Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Invitrogen to Co-Market Cellular Screening Technologies

NEW YORK, Sept. 21 (GenomeWeb News) - PerkinElmer and Invitrogen today said they have inked a co-marketing agreement that will integrate PerkinElmer's CellLux Fluorescence Cellular Screening Platform for cellular screening and Invitrogen's Voltage Sensor Probes ratiometric ion channel reagents.


Peter Coggins, president of PerkinElmer life and analytical sciences, said that the agreement will help both firms' customers "in transitioning to cellular screening, to drive fundamental productivity improvements into the drug discovery and development process."


Nick Ecos, vice president and general manager of Invitrogen's drug discovery solutions business, said the company would seek similar co-marketing agreements in the future. "We will continue to pair our technologies with those from industry-leading companies like PerkinElmer in order to capitalize on our integrated strength," Ecos said.


Financial details were not discussed.


PerkinElmer first disclosed its plan to partner in the cell-based assay market at the Society for Biomolecular Screening earlier this month.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.